PRE trades 105.8% below Wall Street's consensus target of $36.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PRE achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 7, 2026, Prenetics Global Limited (PRE) has a Wall Street consensus price target of $36.00, based on estimates from 1 covering analysts. With the stock currently trading at $17.49, this represents a potential upside of +105.8%. The company has a market capitalization of $297M.
Analyst price targets range from a low of $36.00 to a high of $36.00, representing a 0% spread in expectations. The median target of $36.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PRE trades at a trailing P/E of -6.5x. Analysts expect EPS to grow +22.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
EXASExact Sciences Corporation | $20.0B | $104.91 | $105.00 | +0.1% | Buy | 582.8x | 41 |
NTRANatera, Inc. | $40.6B | $283.80 | $261.00 | -8.0% | Buy | — | 27 |
CSTLCastle Biosciences, Inc. | $734M | $24.21 | $42.80 | +76.8% | Buy | — | 11 |
QDELQuidelOrtho Corporation | $1.2B | $18.00 | $12.25 | -31.9% | Hold | 9.7x | 15 |
AHCOAdaptHealth Corp. | $1.4B | $10.27 | $14.40 | +40.2% | Buy | 12.2x | 12 |
HIMSHims & Hers Health, Inc. | $8.4B | $38.28 | $28.69 | -25.1% | Hold | — | 20 |
MYRGMYR Group Inc. | $6.9B | $442.72 | $412.67 | -6.8% | Hold | 38.7x | 21 |
TMOThermo Fisher Scientific Inc. | $192.4B | $517.60 | $592.45 | +14.5% | Buy | 20.8x | 42 |
DHRDanaher Corporation | $137.0B | $193.62 | $230.89 | +19.2% | Buy | 22.9x | 43 |
IQVIQVIA Holdings Inc. | $35.0B | $205.97 | $222.40 | +8.0% | Buy | 16.1x | 44 |
Quick answers to the most common questions about buying PRE stock.
The consensus Wall Street price target for PRE is $36, representing 105.8% upside from the current price of $17.49. With 1 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
PRE has a consensus rating of "Buy" based on 1 Wall Street analysts. The rating breakdown is predominantly bullish, with 1 Buy/Strong Buy ratings. The consensus 12-month price target of $36 implies 105.8% upside from current levels.
PRE's current price is $17.49 with a consensus target of $36 (105.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $36 for PRE, while the most conservative target is $36. The consensus of $36 represents the median expectation. These targets typically reflect 12-month expectations.
PRE is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PRE stock forecast based on 1 Wall Street analysts shows a consensus price target of $36, with estimates ranging from $36 (bear case) to $36 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on PRE, with a "Buy" consensus rating and $36 price target (105.8% upside). 1 of 1 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PRE analyst price targets range from $36 to $36, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $36 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.